loading page

Protein kinase inhibitors for Amyotrophic Lateral Sclerosis therapy
  • +2
  • Valle Palomo,
  • Vanesa Nozal,
  • Elisa Rojas-Prats,
  • Carmen Gil,
  • Ana Martinez
Valle Palomo
Consejo Superior de Investigaciones Científicas
Author Profile
Vanesa Nozal
Consejo Superior de Investigaciones Científicas
Author Profile
Elisa Rojas-Prats
Consejo Superior de Investigaciones Científicas
Author Profile
Carmen Gil
Consejo Superior de Investigaciones Cientificas
Author Profile
Ana Martinez
Consejo Superior de Investigaciones Científicas
Author Profile

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that causes the progressive loss of motoneurons, and unfortunately, there is no effective treatment to stop the disease. Multiple pathological mechanisms are interconnected in the neuropathology of this disorder, including abnormal aggregation of proteins, neuroinflammation and dysregulation of the ubiquitin proteasome system. Such complex mechanisms, together with the lack of reliable animal models of the disease, have hampered drug discovery in the last decades. Protein kinases, key pharmacological targets in several diseases, have been linked to ALS, as they play a central role in numerous of these pathological mechanisms. Therefore, several inhibitors are currently in their way to achieve a clinical proof of concept in ALS patients. In this review we recapitulate the protein kinase inhibitors currently in development for this disease together with their molecular targets and their involvement in the pathobiology of ALS.

Peer review status:ACCEPTED

25 Apr 2020Submitted to British Journal of Pharmacology
27 Apr 2020Submission Checks Completed
27 Apr 2020Assigned to Editor
28 Apr 2020Reviewer(s) Assigned
16 Jun 2020Review(s) Completed, Editorial Evaluation Pending
16 Jun 2020Editorial Decision: Revise Minor
01 Jul 20201st Revision Received
06 Jul 2020Submission Checks Completed
06 Jul 2020Assigned to Editor
10 Jul 2020Reviewer(s) Assigned
17 Jul 2020Review(s) Completed, Editorial Evaluation Pending
25 Jul 2020Editorial Decision: Accept